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Abstract
Methyl-CpG-binding protein 2 (MECP2) is a multi-functional regulator of gene expression. In humans loss of MECP2 function
causes classic Rett syndrome, but gain of MECP2 function also causes mental retardation. Although mouse models provide
valuable insight into Mecp2 gain and loss of function, the identification of MECP2 genetic targets and interactors remains
time intensive and complicated. This study takes a step toward utilizing Drosophila as a model to identify genetic targets
and cellular consequences of MECP2 gain-of function mutations in neurons, the principle cell type affected in patients with
Rett-related mental retardation. We show that heterologous expression of human MECP2 in Drosophila motoneurons causes
distinct defects in dendritic structure and motor behavior, as reported with MECP2 gain of function in humans and mice.
Multiple lines of evidence suggest that these defects arise from specific MECP2 function. First, neurons with MECP2-induced
dendrite loss show normal membrane currents. Second, dendritic phenotypes require an intact methyl-CpG-binding
domain. Third, dendritic defects are amended by reducing the dose of the chromatin remodeling protein, osa, indicating
that MECP2 may act via chromatin remodeling in Drosophila. MECP2-induced motoneuron dendritic defects cause specific
motor behavior defects that are easy to score in genetic screening. In sum, our data show that some aspects of MECP2
function can be studied in the Drosophila model, thus expanding the repertoire of genetic reagents that can be used to
unravel specific neural functions of MECP2. However, additional genes and signaling pathways identified through such
approaches in Drosophila will require careful validation in the mouse model.
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Introduction
Methyl-CpG-binding protein 2 (MECP2) is a multifunctional
transcriptional regulator involved in chromatin remodeling. Loss
of MECP2 function mutations cause classic Rett Syndrome (RTT)
[1,2], an X-linked, dominant, progressive, neuro-developmental
disorder [3,4]. Patients with RTT suffer from cognitive, language,
motor conditions, and seizures [5,6]. However, MECP2 duplica-
tion is a frequent case of mental retardation and progressive
neurological symptoms in males [7,8,9], and overexpression of
MECP2 in the developing mouse brain also causes progressive
neurological disorder [10,11].
The MECP2 protein contains at least five distinct functional
domains (NTD, ID, MBD, TRD, and CTDa) which either bind
DNA autonomously or regulate MBD (methyl-CpG binding)
function [12]. Historically, MECP2 is viewed as a transcriptional
repressor that localizes to chromatin by binding to CpG
dinucleotides to regulate gene expression through interactions
with histone deacetylases and other cofactors [13,14,15,16].
However, MECP2 can also activate transcription [17], associates
also with un-methylated DNA [12,18,19], has chromatin com-
paction and RNA splicing functions [20,21,22], and several
MECP2 interacting proteins have been identified [2]. Therefore,
multiple MECP2 functions might be mediated by interactions with
diverse co-factors and by binding to both methylated and non-
methylated DNA, consistent with the wide range of phenotypes
observed in patients with RTT.
Although Mecp2 mouse models recapitulate RTT phenotypes
[23,24,25,26,27] and have provided valuable mechanistic insight
into neuronal defects caused by Mecp2 mis-regulation, such as
axon targeting [28], synaptic [29,30], and dendritic [31] defects,
the identification of MECP2 functions and target genes in this
system is time intensive and complicated.
Facile genetic tools [32], short generation times, and a high
degree of conservation in fundamental cell biological pathways
[33] make Drosophila a powerful model to study molecular and
cellular mechanisms underlying mental retardation [34,35,36,37].
It is not expected that Drosophila will recapitulate all details of Rett-
related pathophysiology since its genome is sparsely methylated
[38] and does not contain an ortholog of human MECP2.
However, multiple MECP2 interactors and most components of
the chromatin machinery have well conserved orthologs in flies
[39]. In transgenic flies that express human MECP2, the protein
associates with chromatin, modifies the transcription of multiple
genes, and is phosphorylated at serine 423, as in mammals [40].
Significantly, reported consequences of a MECP2 gain-of-function
in Drosophila are developmental defects and motor dysfunctions,
suggesting close parallels with RTT phenotypes [40].
Our current study expands genetic and behavioral proof of
principle for studying MECP2 gain-of-function phenotypes in
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in identified Drosophila motoneurons results in dendritic defects but
normal membrane properties. MECP2-caused dendritic defects
require an intact MBD domain, can be ameliorated by dose
reduction of the chromatin remodeling protein osa, and cause
specific motor behavioral defects, thus indicating that the
Drosophila model is useful to unravel some aspects of MECP2
function in neurons.
Results
This study used the individually identified flight motoneuron,
MN5, to study effects of targeted expression of human MECP2
variants in Drosophila neurons on dendritic structure and mem-
brane properties. As is the unique advantage of all individually
identified neurons in invertebrate preparations, MN5 can be
unambiguously identified in every individual fly, and it exhibits a
characteristic morphology, membrane properties, and a distinct
function albeit integrated into a network. MN5 is one of only five
MNs innervating the dorsal longitudinal flight muscle (Fig. 1A,
DLM) [41,42] which provides the main force for wing downstroke
during Drosophila flight. MN5 is a large monopolar neuron with its
soma located in the mesothoracic neuromere of the Drosophila
ventral nerve cord (VNC), on the contralateral side with respect to
its target muscle (Fig. 1A), [43]. All MN5 dendrites develop de novo
during pupal life [42], thus allowing for studies of postembryonic
dendritic growth. MN5 dendrites span the dorsal neuropil of the
second thoracic neuromere of the Drosophila ventral nerve cord
(Fig. 1A, dotted green line), and we have shown previously that
MN5 dendritic structure shows reasonably low variation among
control animals, which allows for quantitative studies of the effects
of genetic manipulation [44]. In the adult fly, the dendritic field of
MN5 comprises more than 4000 dendritic branches making up for
more than 6500 mm total length. In addition, we have analyzed
firing responses [43] and membrane currents [45] in control MN5.
We used the UAS-GAL4 system to express three different forms
of human MECP2 using previously constructed transgenes (kindly
provided by Dr. J Botas, Baylor College of Medicine, Houston,
Texas) under the control of motoneuron-specific GAL4 drivers
(C380-GAL4; see methods). The first is full-length human MECP2,
Figure 1. Heterologous expression of MECP2 causes dendritic defects in Drosophila motoneurons. (A) Schematic drawing of location of
MN1-5 in the Drosophila nervous system and their innervation of the dorsal longitudinal flight muscle (DLM) fibers. MN5 is depicted in green, and
MN5 dendritic projection in the dorsal mesothoracic neuromere is demarked by a dotted green line (B) Overview of MN5 structure in a representative
control animal. A geometric reconstruction of MN5 dendritic structure is superimposed on the projection view. (C) Overview of MN5 dendritic
structure following targeted expression of full-length human MECP2. Geometric reconstruction superimposed on projection image of MN5. (D)
Double staining of MN5 (green) and anti-MECP2 immunolabeling (magenta) shows MECP2 localization to MN5 nucleus (white) and some other nuclei
of neurons with C380-GAL4/UAS-MECP2 expression. (E) Same as (D) but anti-MECP2 immunolabeling only to show that no MECP2 protein was
detected through MN5 processes. Inset depicts anti-MECP2 immunostaining in a representative single optical section through MN5 soma and
primary neurite. MN5 outline is demarked by white line, and white arrow demarks MN5 nucleus. MECP2 protein could not be detected in any part of
MN5 except the nucleus. (F) Quantitative metric measures of dendritic structure in MN5 from controls (gray bars) and in MN5 with MECP2 expression
(magenta). Values are normalized to mean control values (dotted line). Arrows indicate statistical significant differences (Students T-test, p#0.01).
Error bars indicate standard deviation. (G and H) Mean number of dendritic branches (G) and mean dendritic radius in controls (gray squares) and
following MECP2 expression (magenta circles) over branch order. Error bars indicate standard deviation. Axis in (H) is clipped at branch order 41
because only few dendrites of higher branch orders exist (see G).
doi:10.1371/journal.pone.0031835.g001
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The R106W allele is a missense mutation that creates a non-
functional methyl-CpG-binding domain (MBD) [46]. In the D166
mutation the MBD and N-terminal portion of the protein are
removed.
Full-length human MECP2 specifically causes dendritic
defects but does not impair normal membrane
excitability in Drosophila motoneurons
Intracellular fills of MN5 in control animals with subsequent
quantitative dendritic architecture reconstruction (Fig. 1B) yielded
the same values for MN5 dendritic tree structure as previously
published [44], but expression of full-length human MECP2 in
MN5 clearly affected MN5 dendritic structure (Figs. 1C, D).
Targeted expression of full-length human MECP2 in MN5 and
few other neurons (see methods for expression patterns of C380-
GAL4; Cha-GAL80) resulted in localization of MECP2 protein to
the nuclei of these neurons, as demonstrated by MECP2
immunocytochemistry (Figs. 1D, E, magenta, see white arrow
for MN5 nucleus). Careful inspection of single optical sections
through MN5 nucleus and dendrites (see inset in figure 1E)
showed that no anti-MECP2 immunopositive label was detectable
outside the nucleus.
Quantitative comparison of MN5 dendritic structure in controls
(Fig. 1B) and following over-expression of MECP2 (Figs. 1C, D)
caused a significant decrease in the number of branches by 60%
(from 4000690 in controls to 1734.856713) which resulted in
significantly decreased total dendritic length by about 50%
(Fig. 1F, from 65176471 mm in controls to 34906816). By
contrast, the mean lengths of the individual dendritic branches was
slightly (20%) but significantly increased (Fig. 1F, from
1.6960.13 mm in controls to 2.0460.26 mm). Therefore, dendritic
branch elongation was not impaired but new branch formation
was strongly reduced by MECP2 expression. Average dendritic
radii were also significantly increased following MECP2 expres-
sion (Fig. 1F, from 0.2360.01 mm in controls to 0.2660.01 mm).
However, dendritic territory borders were not affected as indicated
by normal average distances of the dendrites to their origin
(Fig. 1F, 17.762.1 mm in controls and 16.562.65 mm). Branch
order analysis (Figs. 1G, H) revealed that these dendritic
phenotypes were not restricted to specific branch orders,
indicating that MECP2 affected new dendritic branch formation
and growth during all stages of postembryonic dendritic growth.
Similar conclusions resulted from Sholl analysis which measures
dendritic lengths or dendrite numbers in concentric 3-dimensional
spheres at different distances around the origin of the dendritic
tree (not shown). MN5 dendritic defects as resulting from gain-of-
function of MECP2 were not a result of developmental delay
because intracellular staining of MN5 in three, five, or ten days old
adult flies did not reveal additional dendritic branches (not shown).
By contrast, in progressively older flies MECP2-induced dendritic
defects seemed increasingly more severe, although we did not
quantify this observation.
Electrophysiological recordings in current and in voltage clamp
mode showed that targeted expression of human MECP2 in MN5
did not affect firing properties or potassium membrane currents.
Current clamp recordings revealed no obvious differences in MN5
firing responses to somatic current injections between controls and
following MECP2 expression (Fig. 2A). In situ voltage clamp
recordings from MN5 under cadmium and TTX revealed no
obvious differences in transient A-type or sustained delayed
rectifier type voltage activated potassium currents in controls
and following MECP2 expression (Figs. 2B, C). Quantification of
A-type and delayed rectifier potassium currents revealed no
significant differences in I/V–relationships between controls and
following MECP2 expression (Fig. 2C). In sum, over-expressed
human MECP2 localized to the nucleus in a Drosophila
motoneuron and significantly impaired new dendrite formation
resulting in a reduction of total dendritic length by 50 percent.
However, full-length MECP2 did not affect normal development
of membrane excitability, did not alter dendritic territory borders,
and did not impair dendritic branch elongation. This indicated
that over-expression of MECP2 specifically impaired dendritic
branching but did not have overall deleterious effects on
motoneuron physiology.
Dendritic defects caused by human MECP2 in Drosophila
motoneurons require normal MBD function
Next, we confirmed that dendritic defects as caused by targeted
expression of human MECP2 in Drosophila motoneurons were
dependent on known molecular functions for MECP2, and not
due to non-specific effects that can potentially result from the
expression of a non-endogenous protein. To test whether normal
Figure 2. Heterologous expression of MECP2 does not affect
electrophysiological properties of Drosophila motoneurons.
(A) Comparison of typical MN5 firing responses to 300 pA of somatic
current injection in a representative control animal (left trace) and
following targeted expression of full-length human MECP2 under the
control of C380-GAL4 (right trace). (B) Voltage dependent potassium
currents in MN5 as induced by command voltage steps from a holding
potential of 290 mV to 20 mV in increments of 10 mV and with
cadmium and TTX in the bath solution to block sodium and calcium
inward currents. Traces of control animals (left) and following targeted
expression of MECP2 (right) reveal qualitatively similar transient A-type
current and sustained delayed rectifier like potassium outward currents.
(C) Current/Voltage relationships for A-type (left) and sustained delayed
rectifier (right) potassium currents are quantitatively similar in controls
(gray diamonds) and following expression of MECP2 (magenta
diamonds). Error bars represent standard deviations.
doi:10.1371/journal.pone.0031835.g002
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dendrite development, we expressed two MECP2 transgenes with
non-functional methyl-CpG-binding domains (MBD; Fig. 3A) in
MN5 under the control of the same C380-GAL4 driver that yielded
dendritic defects when used to express full-length MECP2. MBD
domains are required for the two key mechanisms of chromatin
regulation in eukaryotes, C5 methylations of DNA at cytosines and
posttranslational histone modifications [47]. Expression of UAS-
MECP2 with either a mis-sense mutation that creates a non-
functional MBD (Fig. 3B; R106W allele) [46], or with a truncated
MBD and N-terminal portion (Fig. 3C; D166 allele) did not cause
any obvious dendritic defects (Figs. 3B to G). As for full-length
MECP2 (see above) strict nuclear localization of MECP2 was
observed for the R106W and the D166 alleles (Figs. 3D, E; see also
white arrows in figures 3B, C). Quantification of total dendritic
length (Fig. 3H) and the number of dendritic branches (Fig. 3I)
demonstrated that no significant differences existed between
controls or following targeted expression of MECP2 with defective
MBD (Figs. 3H, I; ANOVA with Newman Keuls post hoc testing,
p.0.2). By contrast, expression of full-length human MECP2
caused less total dendritic length (Fig. 3H) and significantly fewer
branches (Fig. 3I) than expression of either R106W or D166
(ANOVA with Newman Keuls post hoc testing, p,0.01).
Therefore, dendritic phenotypes induced by targeted expression
of human MECP2 in Drosophila neurons required an intact MBD,
indicating specific action and not unspecific toxic effects of MECP2
gain-of-function in Drosophila motoneurons.
Dendritic defects in Drosophila motoneurons caused by
gain-of-function of human MECP2 can be ameliorated by
reducing the dose of the BAF250 homolog, osa
Since Drosophila DNA is only sparsely methylated, interactions of
the MBD of MECP2 with C5 methylations of DNA at cytosines
seem unlikely (see discussion). Alternatively, the MECP2 MBD
might interact with posttranslational histone modifications [47].
This is in agreement with previous findings that reduction of osa
function can amend behavioral defects as induced by pan
neuronal expression of human MECP2 in flies [40]. Osa (human
homolog is BAF250) is a member of the SWI/SNF complex, a
class of trithorax proteins involved in chromatin remodeling [48].
To test whether MECP2-induced dendritic defects require normal
function of an intact BAF complex (ATP-dependent chromatin
remodeling complex) we expressed full-length human MECP2 in
MN5 in a heterozygous osa mutant background, which should
lower the dose of functional osa protein. Intracellular labeling of
MN5 in a heterozygous osa mutant background (Fig. 4B) and
subsequent quantification (Fig. 4E) showed that a reduction in osa
dose did not alter dendritic structure as compared to controls
(Figs. 4A, E). However, the heterozygous osa mutant background
significantly ameliorated MECP2-induced dendritic effects in
MN5 (Figs. 4 C, E, F). The strict nuclear localization of MECP2
was not altered by a reduction in osa function (Fig. 4D). Although
total dendritic length and the number of dendrites were
significantly lower as compared to controls, MN5 contained
significantly more dendrites and a larger total dendritic length if
expressed in the presence of reduced osa function as compared to
expression of MECP2 in controls (Fig. 4E). Therefore, dendritic
defects as caused by MECP2 gain-of-function can be partially
rescued by a reduction in osa function, thus indicating functional
interactions of MECP2 and osa. This was also reflected by branch
order analysis. Expression of full-length human MECP2 in an osa
heterozygous mutant background resulted in fewer dendrites
through all branch orders higher than eight as compared to
controls (Fig. 4F), but it resulted in more dendrites per branch
order as compared to expression of full-length MECP2 in a wild
type background (Fig. 4F). By contrast, increased mean length and
radius of individual dendritic branches as induced by targeted
expression of MECP2 were not rescued in an osa mutant
background. In sum, these genetic interaction experiments show
that MECP2-induced MN5 dendritic branch formation defects
require normal osa function, indicating that the MB domain of
MECP2 may interact with the ATP-dependent chromatin
remodeling BAF complex (see discussion).
Motor behavioral consequences of MECP2-induced
dendritic defects
Human RTT patients suffer from motor deficits, and mouse
models recapitulate motor dysfunctions. Similarly, Cukier et al.
[40] reported that expression of full-length human MECP2 in all
cholinergic neurons leads to impaired motor function in a
climbing assay. We tested whether MECP2-induced motoneuron
dendritic defects affected motor performance of adult flies. First, it
is favorable to have an easy to score phenotype to screen potential
genetic rescues in future experiments. Second, it is important to
test what the functional consequences of the specific dendritic
defects reported in this study are. As mentioned above, MN5 is
one out of five flight motoneurons innervating the dorsal
longitudinal flight muscle (DLM, Fig. 1A). In our experiments,
MECP2 was expressed in MN1-5. Therefore, we tested for flight
behavioral defects. First, MN5 firing patterns were recorded
extracellularly with fine tungsten wires during restrained flight (see
methods) [41]. Since Drosophila flight is powered by asynchronous
flight muscles MN1-5 fire only at about every 10
th to 20
th wingbeat
[49]. No obvious differences were found between MN5 firing
patterns during flight in control animals as compared to animals
with MECP2 expression in MN1-5 (Fig. 5A). Similarly, wing beat
frequencies during flight were not different between both groups
(Fig. 5B). Moreover, the likelihood to engage into a flight was not
affected by MECP2-induced motoneuron dendritic defects
(Figs. 5C, D). Neither the percentage of flies taking off in response
to a wind stimulus (Fig. 5C), nor the number of flight bouts that
could be elicited in flies were different between controls and
MECP2 expressing flies. By contrast, flies with MECP2-caused
motoneuron dendritic defects could not maintain flight motor
behavior. The mean duration per flight bout (Fig. 5E) was
drastically reduced in MECP2 flies as compared to control flies, on
average by a factor of 60. Similarly, total flight duration was
significantly reduced in animals with MECP2-caused motoneuron
dendritic defects (Fig. 5F), on average by a factor of 30.
Discussion
Drosophila as a useful genetic model for studies on
MECP2 gain-of-function in neurons
The Drosophila genetic model system is experiencing increasing
use as a tool to analyze specific genetic and cellular aspects of
neurodevelopmental disorders. Short generation times, high
fecundity, high throughput screening techniques, facile genetic
tools, and relatively low costs have provided valuable mechanistic
insights into inherited diseases like Fragile-X, Angelman syn-
drome, and neurofibromatosis [37]. However, despite consider-
able conservation in fundamental cell biological pathways the
Drosophila genome encodes only about 75 percent of human disease
associated genes [50], and mecp2 is not among these genes.
Therefore, Drosophila can not be used to study the pathophysiology
resulting from loss of endogenous mecp2. Instead, the Drosophila
model relies on heterologous expression of human MECP2 allele
and consequential gain of MECP2 function. Although classic Rett
Probing MeCP2 Gain-of-Function in Drosophila
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31835Figure 3. Heterologous expression of MECP2 with MBD defects does not affect Drosophila motoneuron dendrite development. (A)
Schematic drawings of full-length human MECP2 (magenta) with intact menthyl-CpG-binding domain (MBD) and intact transcriptional repression
domain (TRD). The R106W mutation (red) carries a point mutation (see x) that causes a non-functional MBD. The D166 mutation (orange) has a
truncated MBD and N-terminus. TRD is intact in all three alleles. Nuclear localization sequences (nls) have been reported in the inter-domain region at
residues 174 and 190 and also in the TRD domain between residues 255 and 271, and are intact in all three alleles. (B, D, F) Intracellular labeling of
MN5 following R106W expression under the control of C380-GAL4 (B) and subsequent geometric reconstruction (F) do not reveal obvious dendrite
defects in MN5. (D) MECP2 immunolabeling following targeted R106W expression indicates strict nuclear localization (see also white arrow in B). (C, E,
G) Intracellular labeling of MN5 following D166 expression under the control of C380-GAL4 (C) and subsequent geometric reconstruction (G) do not
reveal obvious dendrite defects in MN5. (E) MECP2 immunolabeling following targeted R106W expression indicates strict nuclear localization (see also
white arrow in C). (H) Averages of total dendritic length in controls (gray bars), and following expression of full-length MECP2 (magenta), R106W (red),
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artificial approach since in humans and in mouse models increased
levels of MECP2 also cause disease [7,8,9,10,11]. Genetic and
behavioral proof of principle for the use of the Drosophila model to
address MECP2 gain-of-function has recently been provided [40].
In MECP2 transgenic flies the MECP2 protein associates with
chromatin, interacts with homologs of known human MECP2
interactors, modifies the transcription of multiple genes, and is
phosphorylated at serine 423, as in mammals. Most importantly,
reported consequences are developmental dysfunctions and motor
defects, suggesting parallels with RTT phenotypes. However,
previous work on MECP2 in the Drosophila CNS has not tested for
cellular phenotypes resulting from MECP2 over-expression in
neurons, although mouse models have demonstrated that disease
phenotypes result from Mecp2 mis-regulation in postmitotic
neurons [11]. This study presents the first data on cellular defects
as resulting from MECP2 gain-of-function in developing postmi-
totic Drosophila neurons.
Our data demonstrate that heterologous expression of human
MECP2 in Drosophila motoneurons does not affect axonal
pathfinding, dendritic territory boundaries, or the neurons’
electrophysiology, but it causes a significant reduction in new
Figure 4. MECP2-caused dendrite defects are partially ameliorated by a reduction in osa dose. (A) Projection view of a representative
intracellular staining of MN5 in a control animal. (B) Projection view of a representative intracellular staining of MN5 in an osa heterozygous mutant
background does not reveal obvious differences in dendritic structure as compared to control. (C) Projection view of a representative intracellular
staining of MN5 with heterologous expression of full-length MECP2 in an osa heterozygous mutant background does not show similar dendritic
defects as compared to MECP2 expression in a wildtype osa background (see figures 1C, D). (D) MECP2 immunopositive label (magenta) was
restricted to the nucleus (see also white arrow in C). (E) Quantitative metric measures of dendritic structure in MN5 from controls (dark gray bars),
MN5 in an osa heterozygous mutant background (light gray bars), from MN5 with MECP2 expression (magenta), and from MN5 with MECP2
expression in an osa heterozygous mutant background. Values are normalized to mean control values. Arrows indicate statistical significance (ANOVA
with Newman Keuls posthoc test, p#0.01). Error bars indicate standard deviation. (F) Mean number of dendritic branches over branch order in
controls (gray squares), following MECP2 expression (magenta circles), and following MECP2 expression in an osa heterozygous mutant background
(blue). Error bars indicate standard deviation.
doi:10.1371/journal.pone.0031835.g004
and D166 (orange). (I) Average numbers of dendritic branches in controls (gray bars), and following expression of full-length MECP2 (magenta),
R106W (red), and D166 (orange). In (H) and (I) error bars indicate standard deviation, asterisks demark statistical significance at p#0.05 (ANOVA with
Newman Keuls posthoc test).
doi:10.1371/journal.pone.0031835.g003
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mouse model Mecp2 mis-regulation results in pyramidal neuron
dendritic defects [29,31]. We provide four lines of evidence that
dendritic defects in Drosophila motoneurons are caused by specific
cellular functions that result from MECP2 gain-of-function, and
not from non- specific over-expression or sequestering effects.
First, MECP2 protein specifically localizes to the nucleus of
Drosophila neurons, so that interactions of MECP2 with molecules
in the cytoplasm are unlikely. Second, targeted expression of
MECP2 in Drosophila motoneurons causes significant dendritic
branching defects but does not affect firing responses to current
injections, voltage activated potassium current, or firing frequen-
cies during motor behavior, indicating normal regulation of
electrophysiological properties. Although it has recently been
demonstrated that Drosophila motoneuron dendritic structure may
undergo compensatory changes in response to altered neuronal
activity [51], and a link between motoneuron activity and
dendritic growth has clearly been established [43,52], we did not
find any evidence for homeostatic changes in motoneuron
excitability in response to developmental defects in dendritic
structure. Third, MECP2-induced dendritic defects require intact
MBD function of the MECP2 protein because dendritic
architecture was not affected following expression of MECP2
alleles with non-functional MBD. This indicates that human
MECP2 exerts specific action in Drosophila neurons via chromatin
remodeling (see below). Fourth, MECP2-induced dendritic
Figure 5. MECP2-induced motoneuron defects result in specific motor behavioral deficiencies. (A) Representative extracellular recording
of MN5 firing patterns during flight in a control (upper trace) and in fly expressing MECP2 in a subset of neurons, including MN5 (C380-GAL4, UAS-
mcd8-GFP; Cha-GAL80/UAS-MECP2; lower trace). Traces above the recordings resemble spike counts. Black arrow demarks start of flight, and black
asterisk demarks time point of flight stop in MECP2 fly. (B) Average in-flight wing beat frequencies of control (white bar) and MECP2 flies (grey bar).
Error bars represent standard error. (C) Percentage of control (white bar) and MECP2 flies (grey bar) engaging into flight upon a wind stimulus. (D)
Numbers of flight bouts performed by control (white bar) and by MECP2 flies (grey bar) in response to re-occuring wind stimuli (see methods). Data
are presented as median and quartiles. Error bars represent minimum and maximum values. (E and F) Total duration of all consecutive flight bouts (E)
and average duration of individual flight bouts (F) in control (white bar) and in MECP2 flies (grey bar). Data are presented as median and quartiles.
Error bars represent minimum and maximum values. ** demarks p,0.01, Mann and Whitney U-test.
doi:10.1371/journal.pone.0031835.g005
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member of the SWI/SNF complex. This genetic interaction
experiment is consistent with the hypothesis that human MECP2
may exert specific action in Drosophila motoneurons via chromatin
remodeling. It also indicates that MECP2 gain-of-function
activates specific cell signaling pathways in Drosophila, and may
not cause unspecific over-expression effects. Therefore, we
conclude that Drosophila neurons can serve as a valuable model
system to identify some cellular mechanisms by which MECP2
gain-of-function affects neuronal development.
Potential mechanisms underlying MECP2-induced
dendritic defects in Drosophila neurons
Our data indicate that dendritic defects as induced by
heterologous expression of MECP2 in Drosophila motoneurons
require an intact MBD domain, because expression of MECP2
with a point mutated or truncated MBD domain has no effects on
dendritic structure. However, each UAS-MECP2 transgene is likely
inserted into a unique site in the Drosophila genome, and therefore,
we can’t exclude the possibility that different UAS-MECP2
transgenes may yield different expression levels or other genetic
interactions. For two reasons we judge it unlikely that our finding
that dendritic defects as caused by the expression of full length
UAS-MECP2, but not by the expression of UAS-MECP2 transgenes
with defective MBD domain, were a result of the unique insertion
sites of the UAS-MECP2 constructs into the Drosophila genome.
First, both UAS-transgenes with defective MBD did not cause
dendritic defects. Second, similar dendritic defects were observed
following the expression of the full length MECP2 construct
inserted in the second or in the third chromosome.
MBD domains recognize the two key mechanisms of chromatin
regulation in eukaryotes, C5 methylations of DNA at cytosines and
post-translational histone modifications [47]. Although the exis-
tence of DNA methylation has been demonstrated in the fly
genome [53,54], methylation levels are several orders of
magnitude lower than in mammals. The fly genome contains
only one methylated DNA binding protein (dMBD2/3) and only
one DNA methyltransferase (dDNMT2), which shows highest
affinity to t-RNA. Consequently, Drosophila DNA is only sparsely
methylated, so that MECP2 interactions with modified histone
tails seem the more parsimonious scenario. This is consistent with
our finding that MECP2-dependent dendritic defects are sup-
pressed in an osa heterozygous mutant background. Osa is a
member of the SWI/SNF complex (human homolog is BAF250), a
class of trithorax proteins involved in chromatin remodeling [48]
which are highly conserved between flies and humans. This
indicates that human MECP2 may exert specific action in
Drosophila motoneurons via chromatin remodeling. In fact, it has
previously been suggested that MECP2 associates with human
Brahma, a catalytic component of the SWI/SNF chromatin
remodeling complex to regulate gene repression [20], although
this finding has been disputed [55]. The Drosophila system provides
some unique advantages to study possible interactions of MECP2
and members of the SWI/SNF chromatin remodeling complex
with genetic tools.
MECP2-induced motoneuron dendritic defects cause
specific motor behavioral deficiencies
Our findings that flies with MECP2 over-expression in
motoneurons show normal take-off likelihoods as well as normal
motoneuron firing and wing beat frequencies, but can not sustain
flight are in accord with specific MECP2 effects on dendrite
development in otherwise normal motoneurons. In Drosophila,
take-off can be mediated by the escape response neural circuitry.
This circuitry bypasses flight motoneuron dendrites by synapsing
directly on MN5 axon, but it relies on normal synaptic
transmission and flight motoneuron physiology [56,57]. There-
fore, initial take-off and initial motoneuron firing are not affected
by dendritic defects. In Drosophila motoneuron firing frequencies
are directly proportional to wing beat frequency [58], and thus,
these are also not affected. By contrast, flight can not be sustained
because the significantly reduced dendritic surface likely reduces
the excitatory synaptic drive to motoneuron dendrites [59] that is
necessary to stay in flight. Therefore, flies with MECP2-caused
motoneuron dendritic defects show a 30- to 60-fold reduction in
flight duration. This behavioral phenotype is obvious, and thus,
useful for screening. Although the quantification of flight durations
and take-off likelihoods as presented in figure 5 does not allow for
rapid genetic screening, high throughput screening can easily be
developed based on the observed reduction in flight duration by
more than 30-fold. Moreover, high throughput assays which
utilize Drosophila behavior for rapid screening have been developed
by others [60,61]. Such approaches may help the future
identification of candidate MECP2 targets or interactors.
The use of Drosophila to identify candidate pathways for
non-methylated DNA-dependent functions of MECP2 in
neurons
Historically MECP2 is viewed as a transcriptional repressor that
localizes to chromatin by binding to CpG dinucleotides to regulate
gene expression by interactions with histone deacetylases and
other cofactors [13,14,15,16]. However, MECP2 also binds to
genes that are actively transcribed [17], can associate widely with
un-methylated DNA [12,18,19], interacts with multiple other
proteins [2], and has chromatin compaction and RNA splicing
functions [21,22]. Therefore, multiple MECP2 functions might be
mediated by interactions with diverse co-factors and by binding to
both methylated and non-methylated DNA. Identification of
genetic interactors and modifiers of MECP2 function in neurons
will be imperative toward developing future treatment strategies.
MECP2 itself is not a promising treatment target because the X-
linked MECP2 gene is mosaic regulated in the human brain.
Furthermore, both loss and gain of function cause disease
phenotypes. The sparse methylation landscape in Drosophila may
offer unique promise of identifying non-methylated DNA-
dependent functions of MECP2 in neurons, the cell type that is
most relevant to Rett syndrome. Since known binding partners of
MECP2 are conserved in flies (e.g. YB-1, mSin3A etc.), it seems
plausible that gain-of-function of human MECP2 may affect neural
development via a cellular machinery that is partly conserved
between flies and humans.
MECP2-induced dendritic phenotypes in flight motoneurons cause
a severe motor behavioral phenotype in that flight bout duration is
reduced approximately 30- to 60-fold. Rapid screening assays for
Drosophila behavioral phenotypes are available [60,61]. Combined with
the fast generation times, high fecundity and facile genetic tools
available in Drosophila this offers a powerful tool to identify molecules
that interact with MECP2 in neurons. However, potential MECP2
candidate target genes or genetic modifiers of MECP2 function that
can readily be identified in the Drosophila system will then have to be
further evaluated in the existing mouse models of RTT.
Methods
Animals
Drosophila melanogaster were reared in 68-ml vials on a standard
yeast corn meal agar medium at 25uC and 50–60% humidity with
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after eclosion if not stated otherwise. Fly lines that carry different
permutations of the human MECP2 gene as UAS-transgenes were
kindly provided by Dr. J Botas (Baylor College of Medicine,
Houston, Texas) and were previously published [40]. The first
transgene is full-length human MECP2, and the other ones show
high frequencies of occurrence in patients with RTT. The R106W
allele is a missense mutation in the methyl-CpG-binding domain
(MBD), thus eliminating the protein’s ability to bind methylated
DNA [46]. In the D166 mutation the MBD and N-terminal
portion of the protein are removed. Expression of UAS-MECP2
transgenes in the motoneuron, MN5, was realized by crossing to
recombinant C380-GAL4, UAS-mCD8-GFP; Cha-GAL80 flies which
were obtained from Dr. S Sanyal (Emory University, Atlanta, GA),
and have been described previously [43,52]. C380 expresses in a
subset of motoneurons including MN5, but also in some non-
identified sensory neurons and interneurons [62]. Inclusion of the
Cha-GAL80 transgene inhibited expression in cholinergic sensory
neurons and interneurons, leaving expression in about thirty
neurons per segment in the ventral nerve cord of Drosophila, most
of which are motoneurons. Given this expression pattern, and the
fact that insect motoneurons typically have no output synapses in
the central nervous system [63], phenotypes of individual neurons
following the expression of UAS-MECP2 constructs under the
control of C380-GAL4; Cha-GAL80 are likely to result from cell cell
autonomous signaling. Therefore, possible indirect effects in
motoneurons as resulting from altered neural network properties
seem unlikely, although they can’t be fully excluded. All
morphometric analysis was conducted with female flies. Control
data derived from C380-GAL4, UAS-mCD8-GFP; Cha-GAL80
crossed to w
1118 flies and was consistent with quantitative dendritic
architecture analysis of MN5 in multiple control strains which has
previously been published [44]. Possible interactions between
MECP2 and the chromatin remodeling trithorax protein, osa,
were investigated by expressing human MECP2 under the control
of C380-GAL4 in a heterozygous mutant background for osa. Osa
is a member of the SWI/SNF complex (human homolog is
BAF250), a class of trithorax proteins involved in chromatin
remodeling (Schuettengruber et al., 2007) which are highly
conserved between flies and humans. Standard recombination
protocols were used to cross C380-GAL4, UAS-mCD8-GFP;UAS-
MECP2; Cha-GAL80 into an osa heterozygous mutant background
(osa
00090, loss of function allele, flybase ID: FBal0009367, fly strain
11486 from Bloomington (ry506 P{PZ}osa00090/TM3, ryRK Sb1
Ser1).
Intracellular staining and histology
Thin-walled borosilicate electrodes (resistance of 75–95 MV)
with filament were used to stain the neurons. Electrode tips were
filled with a mixture of 7% Neurobiotin (Linaris GmbH,
Wertheim-Bettingen, Germany) and lysine fixable rhodamin-
dextran 3000 (Invitrogen, Carlsbad, CA) in 2 M potassium
acetate. To prevent dye dilution, an air bubble was left between
the tip and the shaft. After intracellular penetration of MN5, the
dye was injected iontophoretically by applying constant depolar-
izing current of 0.5 nA amplitude for 10–12 minutes. Subse-
quently, the electrode was removed and the ganglia were fixed in
4% paraformaldehyde in phosphate-buffer solution (PBS, 0.1 M,
pH 7.4) for 1 h at room temperature and washed in PBS.
Preparations were washed 6630 min in 0.1 M PBS with 0.5%
Triton X-100. This was followed by 8 washes, 15 minutes each in
PBS. Incubation in Cy3-Streptavidin in PBS (1:750, Invitrogen,
Karlsruhe, Germany) was conducted over night at 4uC. Then,
preparations were washed 6615 min in PBS (0.1 M). Then, the
ganglia were dehydrated in an ascending ethanol-series (50, 70,
90, and 100%, 10 min each). Preparations were cleared and
mounted in methyl salicylate.
Electrophysiology
See previous studies for detail [45,64]. Briefly, wings and legs
were cut and the fly was then pinned dorsal side up in a sylgard
coated Petri dish and submerged in normal saline (composition in
mM: NaCl 128, KCl 2, CaCl2 1.8, MgCl2 4, HEPES 5, sucrose
,35 depending on the osmolality of the solution). pH was adjusted
to 7.25 with 1 M NaOH. Osmolality was adjusted to 290 mOsM/
kg with sucrose. The animal was dissected along the dorsal
midline, and the large dorsal longitudinal flight muscles were
stretched laterally and pinned to expose gut, esophagus, and the
ventral nerve cord (VNC) underneath. After removal of the gut
and the esophagus, the VNC was exposed. The head was removed
to facilitate electrode access to the mesothoracic neuromere. For
rapid saline exchange during experiments the volume of the
recording chamber was minimized by placing a plexiglas ring
(inner diameter 7 mm) around the dissected animal and gluing it
to the dish with petrolatum (volume of recording chamber was
,200 ml). The preparation was then mounted onto an upright
fixed stage Zeiss Axioskop 2 FS plus fluorescence microscope
(Zeiss, Germany) and viewed with a 406 water immersion
objective.
To facilitate access to MN5 with the patch pipette the
ganglionic sheath was focally removed with a large patch pipette
(0.5 MV tip resistance) filled with 2% protease in buffer. This was
done under visual control of the flight motoneurons by fluorescent
excitation of mCD8-GFP. After protease treatment, the prepara-
tion was rinsed with 60 ml normal saline for 10 minutes.
Following protease treatment and rinsing, one of the two available
MN5s was recorded from with a patch pipette (tip-resistance 5.8–
6.5 MV) pulled from borosilicate glass (o.d. 1.5 mm, i.d. 1.0 mm
without filament from World Precision Instruments) with a vertical
pipette puller (Narishige Co., LTD., Japan). For potassium current
recordings electrodes were filled with normal internal solution with
the following composition (in mM): Kgluconate 140, MgCl2 2,
Mg-ATP 2, HEPES 10, EGTA 1.1, glucose to adjust osmolality to
300 mOsM/kg. The pH was adjusted to 7.25 with KOH.
Immunohistochemistry
Immunohistochemistry was performed as described previously
[62]. MN5 intracellular stainings with neurobiotin were visualized
by coupling to Cy3-streptavidin (1:1000) as described previously
[43]. Primary antibodies were Mouse anti-MECP2 (1:1000,
AbCam Ab50005), and mouse anti-GFP (1:400, AbCam
Ab1218). The anti-MECP2 antibody was raised against a C-
terminal peptide of the MECP2 protein. However, immunostain-
ings with an additional MECP2 antibody that was raised to detect
phosphorylated serine 80 in the N-terminal domain of MECP2
(Symansis Cell Signaling Cat # SY-p1205-80) yielded identical
results with regard to localization of MECP2 following targeted
overexpression (not shown). Secondary antibodies were either Cy2
or Cy5-goat anti-mouse (1:1000). Incubation, dehydration,
clearing and mounting were done as previously described [62].
Confocal microscopy
Digital images were captured with a Leica TCS SP2 confocal
laser scanning microscope (Bensheim, Germany) using a Leica
HCX PL APO CS 640 oil-immersion objective (numerical
aperture: 1.2). Intracellular MN5 labeling with neurobiotin and
subsequent coupling to Cy-3 streptavidin were scanned with a
krypton laser with an excitation wavelength of 568 nm. Emission
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were scanned by using a red HeNe laser at an excitation
wavelength of 633 nm, and emission was detected between 640
and 670 nm. Label of anti-GFP was excited with an argon laser at
488 nm and emission was detected between 495 and 530 nm.
Geometric reconstructions and quantitative
morphometry
AMIRA 4.1.1 software (TGS) was used for processing of
confocal image stacks. Geometric reconstructions were conducted
with custom Amira plug-ins as developed in the Duch lab and
described previously [65,66,67]. Quantitative morphometric data
were imported into Microsoft Excel software and Statistica
(StatSoft, Hamburg, Germany) for further analyses. Mann-
Whitney-U test was used for comparison of morphometric
parameters between two different genotypes and one-way
ANOVA was used to determine statistical significance between
genotypes for branch order and Sholl analyses. For figure
production, images were exported from AMIRA as tiff images
and further assembled and labeled in figure panels with
CorelDraw13 (Corel Corporation).
The location of MN5 in the CNS is shown in figure 1A, and the
overall structure of MN5 is depicted in figure 1B. MN5 is a
unipolar cell, and its axon projects into the efferent nerve towards
the DLM flight muscle on the contralateral side relative to the cell
body. Consequently, axon and cell body are connected by a large
primary neurite from which all major dendritic branches arise. To
account for this feature in our morphometric analysis, we defined
all dendritic branches originating from the primary neurite as first-
order branches, virtually eliminating the primary neurite (which is
treated as 0-order branch) between cell body and axon and
therefore collapsing the reconstruction onto one virtual origin.
Every dendritic branch that branches off a first-order branch is
defined as a second-order branch, and any branch branching off
an n-order branch is defined as (n+1)-order branch.
Flight behavioral testing
Behavioral testing was conducted as previously described [68].
Briefly, one day old male flies were immobilized by cold anesthesia
for 20 s and glued (clear glass adhesive (Duro; Pacer Technology,
Rancho Cucamonga, CA)) with head and thorax to a triangle-
shaped copper hook (0.02 mm diameter). Adhesion was achieved
by exposure to UV light for 30 s. The animals were then kept
individually in small chambers containing a filter paper with 10 ml
of a 10% sucrose solution until testing (1–5 h). Then, the fly was
attached to the experimental setup via a clamp to accomplish
stationary flight. For observation, the fly was illuminated from
behind and above (150 W, 15 V; Schott, Elmsford, NY) and fixed
in front of a polystyrene panel. Additionally, it was shielded by
another polystyrene panel from the experimenter. Tarsal contact
with a bead of polystyrene prevented flight initiation before the
experiment started. A digital high-speed camera (1000 pictures per
second; Motion Scope; Redlake Imaging, Morgan Hill, CA) was
positioned behind the test animal. To initiate flight, the fly was
gently aspirated. The fly was aspirated as a stimulation to fly each
time it stopped flying. When no flight reaction was shown after
three consecutive stimulations, the experiment was completed and
the total flight time was recorded (extended flight). Every stimulus
after the first one, to which the fly showed a response, was
recorded. The duration of each flight bout was recorded. Each fly
was filmed during the first few seconds of flight, and the recordings
were saved on a personal computer for later analysis. The person
scoring the flight time was unaware of the treatment group of the
animal. All animals were included in the study, including those
that did not show any flight behavior.
In some flight experiments, MN5 firing patterns were recorded
extracellularly by inserting small tungsten wires (20 mm diameter)
into the dorsal most fiber of the DLM flight muscle [41].
Extracellular potentials were amplified 100-fold (AM-Systems
1700), digitized with a 1401 analogue digital converter (Cam-
bridge Electronic Design), and analyzed with Spike2 software
(Cambridge Electronic Design).
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